|
Kidneys are at the heart of Ixion Biotechnology. The firm is researching a method to use adult pancreatic stem cells to treat diabetes. Ixion aims to direct the growth of these stem cells into insulin-making islet preparations that could then be transplanted into patients with diabetes. The biotechnology firm has already demonstrated in experiments that islet preparation transplantations can reverse diabetes. The stem cells would be allogenic (derived from donated specimens) rather than autogenic (derived from the patient's own body). Grants from the National Institutes of Health are helping fund the company's work.
|
| | | Contact Information | |
Address: |
13709 Progress Blvd., Ste. 207
Alachua, FL 32615
| | Phone: | 386-418-1428 | | Fax: | 386-418-1583 |
|
| Financial
Highlights | | Fiscal Year End: | December |
|
|
Key People
| | • |
Chairman:
Weaver H. Gaines
| | • |
President and Director of Research:
Robert P. Harris
| | • |
Public Relations:
Lisette Hilton
|
|
|
